Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
20 March 2019 | Story Xolisa Mnuwka | Photo Charl Devenish
Stagedoor Finals
Houses Vergeet-My-Nie and NJ van der Merwe won over the judges at the 2019 Stagedoor finals.

‘Vergeet van der Merwe’, a hybrid of female residences Vergeet-my-Nie and NJ van der Merwe, are the 2019 Stagedoor competition’s overall winners. The dynamic girl duo showed up and showed off during the 2019 Stagedoor finals in the Kopanong Auditorium on the UFS Bloemfontein Campus over the weekend.

The girls enthused the audience with a soul-filled sing-off and a relatable theatrical performance, which earned them both the audience’s and the judge’s best votes. Teams Welwitschia and Imperium (Welperium), and Outeniqua and Soetdoring (Outdoring), walked away with the second and third positions respectively, as each of the residences were recognised for team excellence and spirit when it came to creativity and overall acting in each of their performances.

The UFS Stagedoor competition is an annual event that employs first-years to take cognisance of the day-to-day societal issues and pressures that university students are faced with. In 2019, the event was for the first time entirely organised and ran by students for students.

The competition has over the years become a major highlight on UFS students’ arts and culture calendar and continues to be a platform of expression for residence and off-campus first-year students. Stagedoor performances are traditionally themed to tackle modern-day issues such as infrastructure and economic inequality, land reform, and education. However, this year’s competition engaged students in telling their stories without any restrictions, and still being able to effectively examine the pressures that come with varsity life, and many other issues that face South Africa, but more specifically the youth. The 2019 Stagedoor event was successfully coordinated and structured by UFS Bloemfontein Campus SRC: Arts and Culture, Patrick Chirilele, with help from Residence Committee (RC) Culture members.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept